Abstract
Metastasis is the main cause of death for cancer patients, but our ability to improve clinical outcome first requires a better understanding of the dynamics, cellular mechanisms, and kinetics of metastasis. In prostate cancer (PCa), metastatic tumor cells preferentially colonize to bone. However, a lack of applicable mouse models has limited our ability to study this process accurately. Here, we describe a strategy to bypass this limitation: human PCa cells are injected into immunodeficient mice (at tibia, the left ventricle of heart and the iliac artery). Using this novel technique, the metastatic capabilities of these human PCa cells (e.g., colonization and proliferation potential) can be analyzed in bone with an in vivo imaging system.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Morote J, Ropero J, Planas J et al (2012) Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int 111:1031–1036. https://doi.org/10.1111/j.1464-410X.2012.11406.x
Chang A, Autio K, Roach M, Scher H (2014) High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol 11:308–323. https://doi.org/10.1038/nrclinonc.2014.68
Nardella C, Carracedo A, Salmena L, Pandolfi PP (2010) Faithfull modeling of PTEN loss driven diseases in the mouse. Curr Top Microbiol Immunol 347:135–168. https://doi.org/10.1007/82_2010_62
Salvador F, Llorente A, Gomis RR (2019) From latency to overt bone metastasis in breast cancer: potential for treatment and prevention. J Pathol 249:6–18. https://doi.org/10.1002/path.5292
Massagué J, Obenauf AC (2016) Metastatic colonization by circulating tumour cells. Nature 529:298–306
James ND, de Bono JS, Spears MR et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377:338–351. https://doi.org/10.1056/NEJMoa1702900
Sweeney CJ, Chen Y-H, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737–746. https://doi.org/10.1056/NEJMoa1503747
Robinson D, Van Allen EM, Wu YM et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161:1215–1228. https://doi.org/10.1016/j.cell.2015.05.001
Castro E, Romero-Laorden N, Del Pozo A et al (2019) PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol 37:490–503. https://doi.org/10.1200/JCO.18.00358
Obenauf AC, Massagué J (2015) Surviving at a distance: organ-specific metastasis. Trends Cancer 1:76–91
Peinado H, Zhang H, Matei IR et al (2017) Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer 17:302–317
Bubendorf L, Schöpfer A, Wagner U et al (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578–583. https://doi.org/10.1053/hp.2000.6698
Saad F, Olsson C, Schulman CC (2004) Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol 46:731–740. https://doi.org/10.1016/j.eururo.2004.08.016
Hermanova I, Zúñiga-García P, Caro-Maldonado A et al (2020) Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer. J Exp Med 217:e20191787. https://doi.org/10.1084/jem.20191787
Ku SY, Rosario S, Wang Y et al (2017) Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355:78–83. https://doi.org/10.1126/science.aah4199
Hubbard GK, Mutton LN, Khalili M et al (2016) Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer. Cancer Res 76:283–292. https://doi.org/10.1158/0008-5472.CAN-14-3280
Magnon C, Hall SJ, Lin J et al (2013) Autonomic nerve development contributes to prostate cancer progression. Science 12:6142. https://doi.org/10.1126/science.1236361
Torrano V, Valcarcel-Jimenez L, Cortazar AR et al (2016) The metabolic co-regulator PGC1α suppresses prostate cancer metastasis. Nat Cell Biol 18:645–656. https://doi.org/10.1038/ncb3357
Gomez-Cuadrado L, Tracey N, Ma R et al (2017) Mouse models of metastasis: Progress and prospects. Dis Model Mech 10:1061–1074
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Nunez-Olle, M., Guiu, M., Gomis, R.R. (2021). In Vivo Assessment of Metastatic Cell Potential in Prostate Cancer. In: Stein, U.S. (eds) Metastasis. Methods in Molecular Biology, vol 2294. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1350-4_18
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1350-4_18
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1349-8
Online ISBN: 978-1-0716-1350-4
eBook Packages: Springer Protocols